Market Expansion CDI serves over 6,000 customers globally in the anatomical pathology market and has a 7-dye color system, indicating strong differentiation and potential for cross-sell of complementary pathology reagents, kits, and staining solutions to existing international distributors and new regional partners.

Acquisition Momentum CDI’s 2021 acquisition of Anatech Ltd. signals growing scale, expanded product lines, and deeper regional footprints, creating opportunities to upsell integration services, maintenance, and bundled solutions to the combined customer base.

Product Differentiation As the developer of the first commercially available 7-dye color kit for marking cancer margins, CDI demonstrates technological leadership that can be leveraged to pitch premium color-immunohistochemistry (IHC) and margin-detection kits to pathology labs seeking higher accuracy and efficiency.

SME to Growth Fit With 11-50 employees and revenue in the 1M-10M range, CDI is agile but with room to scale; sales conversations can focus on channel partnerships, OEM opportunities, and service contracts that align with a growing sales cycle and international distribution strategies.

Digital & Brand Reach CDI uses modern analytics and marketing tech (Google Analytics, Adobe Experience Cloud) suggesting readiness for targeted digital campaigns; partner with CDI on co-branded marketing, webinars, and case studies to accelerate lead generation in key regions and institutions.